The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Phase Ib study of JNJ-4496 in R/R LBCL: early safety & efficacy data
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, comments on the early safety and efficacy of JNJ-90014496 (JNJ-4496), a CD19xCD20-targeting autologous CAR T-cell, in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Patel highlights that the CAR T-cell was well-tolerated, with most cytokine release syndrome (CRS) being grade 1, and only a small percentage of patients experiencing immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So JNJ-4496 is a CD19xCD20 targeting autologous CAR T-cell. We presented data at ICML and EHA on the global Phase Ib study of this CAR T cell in patients with relapsed/refractory large B-cell lymphoma. So the patients in the study had had two or more prior lines of therapy or one if they were not eligible for transplantation and we presented safety data at the meeting and then initial efficacy results...
So JNJ-4496 is a CD19xCD20 targeting autologous CAR T-cell. We presented data at ICML and EHA on the global Phase Ib study of this CAR T cell in patients with relapsed/refractory large B-cell lymphoma. So the patients in the study had had two or more prior lines of therapy or one if they were not eligible for transplantation and we presented safety data at the meeting and then initial efficacy results. And so maybe highlight the safety data. This CAR T-cell was really quite well tolerated and had very few high-grade CAR-T-associated toxicities. So overall most CRS was grade one. There was no grade three, four CRS seen at the recommended Phase II dose. And then in terms of ICANS, excitingly there was very little ICANS at the recommended phase two dose. We saw only two patients, so eight percent of the cohort who had ICANS, so the majority of patients treated had no neurologic toxicities at the recommended Phase II dose. And then in terms of efficacy we reported the response rates for the CAR T-cell which were very high and recommended Phase II dose was around 96% ORR and the complete response rate was around 78%. The follow-up is still short so we’re excited to see what the durability of that response looks like but so far things are looking very exciting for that CAR T-cell.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
